Detection MicroRNAs as potential biomarkers non invasive and targeted therapy for several cancer

Y. Bintoro, A Surono, Sofia M Haryana


MicroRNAs (MiRNAs) is small molecule non coding RNAs that consist of 18-25 nucleotide. It is important to control gene expression by affected post transcriptional and translational repression of mRNA. This RNA molecule may as oncogene miRNA (OncomiR) or tumor supresor gene (TSmiR). Lowest or enhanced of miRNA associated to increase development cancer cell, cardiovascular disease, metabolisme disease and immune disorders. The
advantages of miRNA is about their stability in cell, body fluid that always stable under harsh condition as high temperature, different pH values, repeated freeze-thaw cycles and longtime storage. They are present not only in blood but also in formaline-fixed and paraffin embedded years before.The detection of miRNA in blood plasma and serum has potential for earlier cancer diagnostic and prognostic and response to therapy. In this review, providing researchers to increase understanding a glance of miRNA, biogenesis and their function.Better understanding may help to find spesifict biomarker for diagnosis and prognosis also to predict cancer targeted therapy.

Full Text:



R.C. Lee, R.L. Feinbaum, V. Ambros, 1993. The C. elegansheterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14, Cell 75:843–854.

Axtell, M.J., Westholm, J.O., and Lai, E.C. 2011. Vive la difference: biogenesis and evolution of microRNAs in plants and animals. Genome Biol. 12, 221.

Flynt, A.S., and Lai, E.C. 2008. Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat. Rev. Genet. 9, 831–842.

Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Blelloch R, Harber M, Norris MD, Lengyel P, Hackett CS, Preiss T, Chetcuti A, Sullivan CS, Marcusson EG, Weiss W, L’Etoile N, Goga A, 2010: miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN amplified neuroblastoma. Nat Med. 16:1134–1140.

Kim, V. N., 2005. MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol.

Cell Biol. 6, 376–385.

Bartel, D. P., 2009. MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233.

Höck, J. & Meister, G., 2008. The Argonaute protein family. Genome Biol. 9, 210.

Suzuki, H. I. and Miyazono, K., 2011. Emerging complexity of microRNA generation cascades. J. Biochem. 149, 15–25.

Kim, J. Han, M.C. Siomi, 2009. Biogenesis of small RNAs in animals, Nat. Rev.Mol. Cell Biol. 10:126–139.

J. Han, Y. Lee, K.H. Yeom, Y.K. Kim, H. Jin, Kim, 2004. The Drosha-DGCR8 complex in primary microRNA processing, Genes Dev. 18: 3016–3027.

G. Hutvagner, J. McLachlan, A.E. Pasquinelli, E. Balint, T. Tuschl, P.D. Zamore, 2001.Acellular function for the RNA-interference enzyme Dicer in the maturation ofthe let-7 small temporal RNA, Science (New York, NY) 293:834–838.

Qin,W. et al., 2010.miR-24 regulates apoptosis by targeting the openreading frame (ORF) region of FAF1 in cancer cells. PLoS One, 5.

Moretti, F., 2010. Mechanism of translational regulation by miR-2from sites in the 5’ untranslated region or the open reading frame. RNA,16, 2493–2502.

Hwang, H. W., 2007. A hexanucleotide element directs microRNAnuclear import. Science,315: 97–100.

Valadi, H., 2007. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. CellBiol., 9, 654–659.

Hanash, S. M., Baik, C. S., andKallioniemi, O., 2011. Emergingmolecular biomarkers–bloodbasedstrategies to detect andmonitor cancer. Nat. Rev.Clin. Oncol. 8, 142–150.

Chim, S. S., Shing, T. K., Hung, E.C., Leung, T. Y., Lau, T. K., Chiu, R. W., 2008. Detection and characterization of placentalmicroRNAs in maternal plasma.Clin. Chem. 54, 482–490.

Lawrie, C. H., Gal, S., Dunlop, H.M., Pushkaran, B., Liggins, A.P., Pulford, K.,2008.

Detection of elevated levels oftumour-associated microRNAsin serum of patients with diffuselarge B-cell lymphoma. Br.J. Haematol. 141, 672–675.

Calin, G. A. and Croce, C. M., 2006. MicroRNA signatures in human cancers. Nat. Rev.Cancer 6, 857–66.

Nam, E. J., 2008. MicroRNA expression profiles in serous ovarian carcinoma. Clin. Cancer Res. 14, 2690–2695.

Schetter, A.J., 2008.MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299, 425–436.

Hanke, M., 2010.A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol.28, 655–661.

Hu, Z., 2010.Serum microRNA signatures identified in a genome-wide serum microRNAexpression profiling predict survival of non-small-cell lung cancer. J. Clin. Oncol.28,1721–1726.

Mar-Aguilar, F., Mendoza-Ramirez,J. A., Malagon-Santiago, I.,Espino-Silva, P.K.,Santuario-Facio,S. K., Ruiz-Flores, P., 2013.Serum circulating microRNA profilingfor

identification of potentialbreast cancer biomarkers. Dis.Markers34, 163–169.

Si, H., Sun, X., Chen, Y., Cao, Y.,Chen, S., Wang, H., 2013. Circulating microRNA-92a and microRNA-21 as novel minimallyinvasive biomarkers forprimary breast cancer. J. CancerRes. Clin. Oncol. 139, 223–229.

Zeng, R. C., Zhang, W., Yan, X. Q.,Ye, Z. Q., Chen, E. D., Huang, D.P., 2013. Downregulation ofmiRNA-30a in human plasma is anovel marker for breast cancer. Med.Oncol. 30, 477.

Fu, H. J.,2006A novel method to monitor the expression of microRNAs. Mol. Biotechnol. 32,197–204.


  • There are currently no refbacks.